Genomic-adjusted radiation dose to personalise radiotherapy
Menée à partir de données portant sur 1 615 patients atteints d'un cancer (sein, tête et du cou, poumon non à petites cellules, pancréas, endomètre, mélanome ou gliome), cette étude évalue l'association entre l'effet biologique de la radiothérapie, quantifié à l'aide du modèle prédictif GARD (genomic-adjusted radiation dose), et le délai avant une première récidive ainsi que la survie globale
In The Lancet Oncology, Jacob Scott and colleagues describe an algorithm using the genomic-adjusted radiation dose (GARD) to personalise radiotherapy dose prescription on the basis of the biological effect of the dose rather than on physical dose alone. GARD is a preclinically and clinically validated combination of a gene expression assay, which assumes pan-tissue biological networks of radiosensitivity and radioresistance, with a linear quadratic model for estimation of total radiation dose in tissues. In previous work, the investigators identified a tumour molecular signature based on the expression of ten genes (AR, cJun [JUN], STAT1, PKC-
β [PRKCB], RelA [RELA], cABL [ABL], SUMO1, PAK2, HDAC1, and IRF1) that correlated with radiosensitivity (expressed as tumour cell survival fraction per 2 Gy fraction) in a number of cancer cell lines, called the radiosensitivity index (RSI).
The Lancet Oncology , commentaire, 2020